Current status of glioma therapy / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy
;
(12): 1596-1600, 2021.
Article
in Chinese
| WPRIM
| ID: wpr-909253
ABSTRACT
Gliomas are a group of refractory heterogeneous diseases. Gliomas even at the same pathological type and grade exhibit different outcomes after treatment. Therefore, glioma patients have obvious survival difference. The development of intraoperative auxiliary means has greatly contributed to surgical resection of glioma and remarkably increased therapeutic effects. The development of sensitizer realizes the combination of radiotherapy and chemotherapy and can improve the anti-tumor effects of oral temozolomide. Molecular markers and signal pathways involved in glioma, such as isocitrate dehydrogenase-1 mutation, epidermal growth factor amplification, high expression of vascular endothelial growth factor, Notch signal pathway, miRNA, etc. are involved in the occurrence and development of glioma and have an obvious impact on the proliferation, metastasis and invasion of glioma. They are potential molecular targets for the clinical treatment of glioma. Many different immunotherapy schemes are actively carried out in patients with glioma, but the unique tumor immune microenvironment of the central nervous system needs to be considered. This paper reviews the treatment progress of glioma in recent years.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Primary Medicine and Pharmacy
Year:
2021
Type:
Article
Similar
MEDLINE
...
LILACS
LIS